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driving to stenosis and/or leaks. Many compounds, such as pergolide, cabergoline, 
fenfl uramine, ectasy were described as inducers of fi brotic valvular lesions, a rare but 
severe drug reaction. All these drugs share in common the pharmacological property 
to activate a serotonergic receptor subtype, the 5HT2B. Together with the well known 
“carcinoid heart” that is a valvulopathy due to high amounts of circulating serotonin, 
these observations lead to the hypothesis that cardiac valves express a “serotonergic 
system” that could be activated by 5-HT or 5-HTR agonists. The aim of this work 
was to characterize the pattern of expression of 5-HT2A,2B,4 receptors and the serotonin 
transporter (SERT) in various valvulopathies.
Thirty degenerated human valves were collected: 6 calcifi ed aortic valves (CAV), 
5 sclerotic aortic valves (SAV), 6 dystrophic mitral valves (DMV). They were analyzed 
by RT-qPCR and immunohistochemistery.
All samples express 5HT2A,2B,4 receptors and SERT. In these valve tissues, the 
amount of 5HT2B receptor (5HT2B R) mRNA is higher than the 5HT2A one (5HT2A R) : 
Δ Ct (5HT2B R -18S)=12,59±1,42 vs Δ Ct (5HT2A R -18S)=16,98±1,14 for CAV, Δ Ct 
(5HT2B R -18S)=13,04±2,62 vs Δ Ct (5HT2A R -18S)=15,61±1,35 for SAV, Δ Ct (5HT2B 
R -18S)=12,33±0,99 vs Δ Ct (5HT2A R -18S)=16,51±0,72 for DMV. The amounts of 
SERT and 5HT4 receptor mRNA are negligible whatever valve and etiology.
At a topographical point of view, 5HT2BR expression is highly found in endothelial 
cells but is also expressed in some interstitial cells. Characterization of these cells 
is in progress.
To summarize, 5HT2A,2B,4 receptors and SERT are expressed in aortic and mitral 
diseased valves. The amounts of 5HT2A,2B R mRNA are equal between mitral and aortic 
valves. A tendency to a higher 5HT2A,2B R mRNA expression is observed in mitral 
Barlow valves. The contribution of the two 5-HT2 receptors in valve degeneration is 
now under investigation by organotypic and cell cultures.
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Does loss of FlnA-PTP-N12 interaction determines Filamin A associated 
valvular dystrophy?
Damien Duval 
Institut du thorax UMR 1087, Nantes, France
Mutations in the FLNA gene that encodes Filamin A (FlnA) an actin binding 
protein involved in actin cytoskeleton organization were identifi ed in X-linked 
Valvular Dystrophy (XVD). Recently, a baby bearing the FlnA-P637Q FlnA 
mutation was born with a mitral valve prolapse suggesting the implication of FlnA 
mutation in cellular signaling pathways potentially involved in valvulogenesis. To 
analyze the effects of FlnA-P637Q and G288R mutations, I established stable cell 
lines expressing FlnA-WT and FlnA mutations from a FlnA knock-out cell line. 
FlnA-P637Q and G288R expressing cells exhibit impaired adhesion, spreading 
and migration capacities suggesting cellular signaling pathways dysregulation. In 
addition, we showed increased phospho-ERK in FlnA-P637Q vs FlnA-WT cells. 
To evaluate the impact of FlnA mutations on protein interaction, we performed a 
yeast two hybrid screen and identifi ed the tyrosine phosphatase protein (PTP-N12) 
as a FlnA binding partner. Interestingly, PTPN12 is known to regulate cell adhesion 
and migration through the dephosphorylation of p130Cas, FAK, SRC and small 
GTPses GEFs and GAPs. It also regulates ERK signaling pathways through SRC 
kinase, and Grb2-SOS dephosphorylation.
Now, we showed that FlnA mutations impede its interaction with PTP-N12 and 
that PTP-N12 depletion (using siRNA) decreased ERK phosphorylation but restored 
mutant FlnA cells adhesion and migration capacities.
Together, our data showed that FlnA mutations specifi cally alter its interaction 
with the tyrosine phosphatase PTP-N12. We speculate this loss of interaction may 
affect PTP-N12 localization and disturb its regulatory role on ERK, cell-extracellular 
matrix interaction and mechanical stress signaling cascades. All these signaling 
pathways are known to be important physiopathological pathways in valvulopathies 
and there roles are now under studies.
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Positron emission tomography/computed tomography for diagnosis of 
prosthetic valve endocarditis: increased valvular 18F-fl uorodeoxyglucose 
uptake as a novel major criterion
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Background: The diagnosis of prosthetic valve endocarditis (PVE) remains 
challenging. In PVE cases, initial echocardiography is normal or inconclusive in 
almost 30% of cases, leading to a decreased diagnostic accuracy for the modifi ed 
Duke criteria. We sought to determine the value of 18F-fl uorodeoxyglucose positron 
emission tomography/computed tomography (18F-FDG PET/CT) for diagnosing PVE.
Methods: We prospectively studied 72 consecutive patients suspected of having 
PVE. All of the patients were subjected to clinical, microbiological, and echocardio-
graphic evaluation. Cardiac PET/CT was performed at admission. The fi nal diagnosis 
was defi ned according to the clinical and/or pathological modifi ed Duke criteria 
determined during a 3-month follow-up.
Results: A total of 36 (50%) patients exhibited abnormal FDG uptake around 
the site of the prosthetic valve. The sensitivity, specifi city, positive predictive value, 
negative predictive value, and global accuracy were as follows (95% confi dence 
interval): 73% (54%-87%), 80% (56%-93%), 85% (64%-95%), 67% (45%-84%), and 
76% (63%-86%), respectively. Adding abnormal FDG uptake around the prosthetic 
valve as a new major criterion signifi cantly increased the sensitivity of the modifi ed 
Duke criteria at admission [70% (52%-83%) vs 97% (83%-99%), p=0.008]. This 
result was due to a signifi cant reduction (p<0.0001) in the number of possible PVE 
cases from 40 (56%) to 23 (32%).
Conclusions: The use of 18F-FDG PET/CT is helpful for diagnosing PVE. The 
results of this study support the addition of abnormal FDG uptake as a novel major 
criterion for PVE.
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Characterization of the serotonergic system in pathological human cardiac 
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Valvular heart disease (VHD) is a common feature especially in elderly. Two 
types of VHD can be considered: congenital and acquired. Acquired VHD is a 
complex physiopathological entity where valve structure and function are affected 
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Results: The study population included 70 patients (mean age 81.3±5.4 years, 
33 M). Edward valves were implanted in 57 patients (81.4%) and Corevalves in 
13 patients (18.6%). The mean follow-up was 10.1±5.9 days. Complete AV block 
occurred in 3 (4.3 %) patients and resulted in PM implantation. In 3 other patients 
(4.3%), AV block was transient. Patients with pre existing right bundle branch block 
and those who received a CoreValve tended to have complete AV block requiring 
a PM more frequently. After the procedure, PR interval increased signifi cantly of 
12.2±19.9 ms (p<0.001) and QRS width of 16.4±25.1 ms (p<0.001) with frequent 
left bundle branch block.
Conclusion: Our study confi rms the high prevalence of conduction disturbances 
occurring after TAVR. Patients with previous right bundle branch block or implanted 
with a Corevalve tended to have AV block more frequently.
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Background: The intracranial haemorrhages (ICH) represent up to 30% of 
neurological complications of endocarditis. These complications lead to an excess 
mortality and complicate the achievement of valvular surgery.
We aimed (1) to determine predictors of ICH, (2) and to describe their management 
and prognosis in a reference centre.
Methods: In a retrospective study, all consecutive patients with defi nite infective 
endocarditis were included. Clinical, biological, microbiological, echocardiographic 
and complications evaluations were performed on all patients. ICH were assessed 
by using cerebral computed tomography and/or magnetic resonance imaging, and 
cerebral angiography. Predictors of ICH were determined by logistic regression 
analysis.
Results: Among the 533 patients included, 34 (6.4%) experienced ICH. We found 12 
(2.3%) intracranial haemorrhagic conversions, 11 (2.1%) rupture of infectious aneurysms 
(IA), and 11 (2.1%) septic erosion of the arterial wall without A. Multivariable analysis 
identifi ed thrombocytopenia and the presence of a previous cerebral embolism as the 
main predictors of ICH.
Among the patients with ICH, 5 (15%) died because of this complication, 19 
(56%) were treated medically, 7 (21%) had a neurosurgical procedure and 3 (9%) had 
an interventional endovascular treatment. Of the 27 (79%) patients with an indication 
of valvular surgery, 3 (11%) died, 6 (22%) were contraindicated because of their 
neurological status, 2 (7%) were contraindicated for another cause and 16 (59%) 
were operated (8 during the antibiotic period [median time=23 days after the ICH]; 
and 8 after the antibiotic period, [median time=85 days after ICH]). No postoperative 
neurological deterioration was observed. 
Conclusion: -The predictors of ICH in endocarditis are: thrombocytopenia and 
the presence of a cerebral embolism. If a surgical indication persists, the presence of an 
ICH is not always a formal contraindication and must be managed by a multidisciplinary 
approach.
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Background: Cardiac valves calcifi cations (VC) are frequent in chronic hemo-
dialysis and have similar prognostic importance as the presence of atherosclerotic 
vascular disease. This study investigates the prevalence and the risk factors of cardiac 
valves calcifi cation in maintenance hemodialysis.
Material and Methods: Twenty-seven patients on HD (14 men, 13 women, mean 
age 57±11 years, mean HD duration 86.2±75 months) underwent echocardiography 
to screen the presence of VC. Antecedents, calcium and vitamin D intakes, blood 
pressure, BMI, and Kt/v (hemodialysis dose) were determined. Biological parameters 
studied were: calcium, phosphorus, Ca × P product, albumin, iPTH, 25OH vitamin 
D, alkaline phosphatase, hemoglobin, intact parathyroid hormone, total cholesterol, 
LDL, HDL and triglyceride.
Results: Cardiac VC were diagnosed in 13 patients (48.1%). Seven of these patients 
had mitral VC, 2 had aortic VC, and 4 had calcifi cation of both valves. In comparison 
with the group without VC, patients with VC were slightly older (58 vs 57 years) and 
had shorter mean duration of dialysis (81 vs 91 months). Diabetes was more frequent in 
patients without VC (42.8% vs 23.1%). Group with VC had higher BMI (27±5 vs 25±6 
Kg/m2), diastolic BP (72±7 vs 69±10 mmHg), triglyceride (1.88±1 vs 1.72±1 g/l) and 25 
OH vitamin D levels (24±10 vs 21±10 μg/l); and lower hemoglobin (10.2±2 vs 11.5±2 
g/dl), HDL (0.38±0.08 vs 0.41±0.09 g/l), iPTH (430 vs 636 pg/ mL) and AlP levels 
(100.3±37 vs 131.2±70 IU/l). No signifi cant differences were found concerning oral 
calcic and vitamin D intakes, Kt/v, calcium, phosphorus, mean Ca × P product or albumin.
Conclusion: Our results confi rm the increased prevalence of VC in HD patients 
and support careful monitoring of BMI, diastolic BP, lipid parameters and anemia. 
More attention should be focused on screening for this clinically silent complication 
in the earlier stages of chronic renal disease to identify treatment strategies to prevent 
or retard its progression and associated morbidity and mortality.
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Background: Transcatheter aortic valve replacement (TAVR) is a recent alternative 
to surgical valve replacement in patients at high risk for surgery. First observational 
studies of this technique reported a relatively high prevalence of perioperative conduction 
disturbances. We sought to evaluate the prevalence of this complication in our center. 
Methods: We analyzed retrospectively electrocardiograms of patients who underwent 
TAVR between February 2009 and March 2011 in our center. Patients already implanted 
with a pacemaker (PM) were excluded. The main objective was to evaluate the prevalence 
of conduction disturbances requiring PM implantation as well as the prevalence of 
transient AV or bundle branch block during the intra hospital period after TAVR. 
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Background: Early valve surgery reduces the incidence of embolism in patients 
with endocarditis, however the quantifi cation of the embolic risk (ER) is challenging 
in guiding therapeutic decisions.
Table – Abstract 126 – Predictors of ICH
Univariable analysis Multivariable analysis P value
P value OR (95% CI)
Age <0.005
Male gender 0.099 2.9 (1.017-8.2) 0.046
IVDA 0.030
Embolic event
Peripheral
Cerebral
<0.005
<0.005
<0.005 4.9 (2.3-10.5) <0.005
Prosthetic valve IE 0.034
Moderate to severe regurgitation 0.032
Staphylocuccus aureus <0.005
Theombocytopenia <150 Giga/l <0.005 3.2 (1.48-7) <0.005
Methods: In a multicenter observational cohort study, we aimed to develop and 
validate a model to quantify the ER at admission of patients with infective endocarditis. 
From 1,022 consecutive patients presenting with a defi nite diagnosis of infective 
endocarditis, 847 were randomized into derivation (n=565) and validation (n=282) 
samples. Clinical, microbiological and echocardiographic data were collected at 
admission. The primary endpoint was symptomatic embolism that occurred during 
the 6-month period following the initiation of treatment. The prediction model was 
developed and validated accounting for competing risks.
Results: The 6-month incidence of embolism was similar in the development and 
validation samples (8.5% in the two samples). Eight variables were associated with 
the ER and used to create the model: age, diabetes, atrial fi brillation, embolism before 
antibiotics, mitral localization, vegetation length, Staphylococcus aureus, and bacterial 
etiology other than oral streptococci. There was an excellent correlation between the 
predicted and observed ER both in the development and validation samples. The c statistics 
for the development and validation samples were 0.73 and 0.64, respectively. Finally, a 
signifi cant higher cumulative incidence of embolic events was observed in patients with a 
high predicted ER both in the development (p<0.001) and validation (p=0.046) samples.
Conclusions: This model is a simple and accurate tool to quantify the ER at 
admission. It might be used to evaluate the potential benefi t of early surgery.
